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Radiation holidays stimulate tumor immunity
Laura Surace, Matthias Guckenberger and Maries van den Broek
Radiotherapy is a standard treatment for cancer and 
is used since a long time as a stand-alone therapy or in 
combination with surgery and systemic therapies including 
immunotherapy. Its acts through induction of irreversible 
DNA damage to which tumor cells are more susceptible 
because of frequent mutations in DNA repair pathways.
Fractioned radiotherapy, given as daily low doses 
during multiple weeks, was established as standard 
protocol in the clinics because it allows recovery of normal 
tissues. Recently, new technologies were developed that 
more precisely target radiation to the tumor enabling the 
delivery of high doses in fewer fractions (hypofractionated 
or stereotactic radiotherapy) [1].
Recent data suggest that radiotherapy promotes 
an inflammatory response in the tumor, which supports 
tumor-specific immunity and actually, efficacy in pre-
clinical models seems to depend on concomitant immune 
stimulation [2-4].
Inflammation is a useful response to disturbance 
including infection and tissue damage and is instrumental 
in clearing pathogens and necrotic cells as well as in 
tissue repair. Moreover, inflammation provides essential 
innate stimuli to the subsequent activation of protective 
adaptive immunity. Because inflammation is a potent 
and destructive response, it must be tightly regulated and 
resolve as soon as the trigger is eliminated.
Acute inflammation is a relatively short and self-
limiting process that culminates in the recruitment and 
activation of immune cells to the site of action through the 
production of growth factors, cytokines and chemokines. 
When the trigger is gone, the production of anti-
inflammatory cells and factors terminates this process. In 
case of a persisting stimulus, which can be an infectious 
agent, cancer or chronic disturbance, the inflammatory 
reaction is not resolved but becomes chronic. In order 
to limit excessive tissue damage, the nature of the 
inflammatory responses changes under chronic conditions 
and displays features of simultaneous tissue destruction 
and repair, angiogenesis and immunosuppression.
Chronic inflammation was correlated with cancer in 
1858 by Virchow and is now considered an established 
hallmark for cancer [5]. Paradoxically, Coley reported 
in 1893 injection of heat-killed bacteria (Coley’s toxin) 
resulted in tumor regression. This apparent contradiction 
may be explained by the nature of the inflammation: 
Chronic inflammation is tumor-promoting, whereas acute 
inflammation supports protective anti-tumor immunity [6].
Along this line, we showed in mice with 
established, syngeneic tumors that a single dose of 20 
Gy controls tumor progression and promotes a local, 
transient activation of complement, a potent pro-
inflammatory pathway. This resulted in local production 
of anaphylatoxins (C3a and C5a) that proved crucial to 
the stimulation of tumor-specific immunity and therapeutic 
efficacy [3]. When we treated mice with established tumors 
with fractions of 1.5 or 7 Gy delivered on 5 consecutive 
days tumor progression was inhibited as well, but neither 
increased infiltration by leukocytes, specifically CD8+ T 
cells, nor protective effector function of such T cells was 
observed in chronically irradiated tumors [3]. In addition, 
our data show that each dose induces complement 
activation, which results in a state of chronic activation 
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Figure 1: Avoiding chronic inflammation through the 
use of hypo-fractionated radiotherapy with radiation 
holidays. (A) Standard hyper-fractionated radiotherapy 
is given as daily fractions of 1.5-2 Gy during a prolonged 
period. This protocol results in chronic inflammation, which is 
immunosuppressive, supports angiogenesis and is a hallmark of 
progressive cancer. (B) We propose to give hypo-fractionated 
radiotherapy as isolated high-dose fractions with radiation 
holidays between the treatments. This protocol results in 
repeated peaks of acute inflammation, which stimulate protective 
immunity.
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if radiation is given over a prolonged time on consecutive 
days. The lack of increased infiltration by leukocytes and 
specifically of CD8+ T cells on the one hand and increased 
infiltration by regulatory T cells on the other hand after 
5 irradiations can be explained by radiosensitivity of 
effector T cells that were recruited after the first dose and 
by immunosuppressive chronic inflammation resulting 
from multiple irradiations. These observations explain 
the apparently conflicting data by Elvington showing 
that inhibition of C3 activation improves the efficacy of 
fractionated radiotherapy [7]. 
Taken together, we propose that daily radiotherapy 
results in a chronic inflammatory phenotype that does 
not promote immune effector but rather regulatory T 
cells, whereas a single dose and presumably also to 
repeated doses given with yet to be determined interval 
results in repeated peaks of immune stimulating, acute 
inflammation.
Although many aspects are still unknown and 
require further investigation, we speculate that irradiation 
with few radiotherapy fractions of higher dose and with 
a break between the fractions may result in superior 
therapeutic responses compared to daily treatments 
(Figure 1). 
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